Mark Isaac Kaplan

A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes

Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we...